Resectable Gastric Carcinoma Clinical Trials

1 recruiting

Resectable Gastric Carcinoma Trials at a Glance

5 actively recruiting trials for resectable gastric carcinoma are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 1 with 2 trials, with the heaviest enrollment activity in New York, Houston, and Bethesda. Lead sponsors running resectable gastric carcinoma studies include National Cancer Institute (NCI), Mayo Clinic, and Memorial Sloan Kettering Cancer Center.

Browse resectable gastric carcinoma trials by phase

Treatments under study

About Resectable Gastric Carcinoma Clinical Trials

Looking for clinical trials for Resectable Gastric Carcinoma? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Resectable Gastric Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Resectable Gastric Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 15 of 5 trials

Recruiting
Phase 1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+37 more
National Cancer Institute (NCI)51 enrolled23 locationsNCT04704661
Recruiting
Phase 1

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+10 more
National Cancer Institute (NCI)48 enrolled1 locationNCT06364410
Recruiting
Not Applicable

Intravital Microscopy in Human Solid Tumors

Malignant Brain NeoplasmMalignant Solid NeoplasmAnatomic Stage IV Breast Cancer AJCC v8+20 more
Mayo Clinic85 enrolled1 locationNCT03823144
Recruiting
Phase 2

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Metastatic Gastric AdenocarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaUnresectable Gastric Adenocarcinoma+10 more
Memorial Sloan Kettering Cancer Center37 enrolled7 locationsNCT06251973
Recruiting
Phase 2

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Metastatic Gastric CancerUnresectable Gastric CarcinomaHER2-positive Gastric Cancer
Qilu Hospital of Shandong University110 enrolled20 locationsNCT06730373